Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.

Feng, Zhen; Li, Xiaoye; Tong, Wai Kei; He, Qingfeng; Zhu, Xiao; Xiang, Xiaoqiang; Tang, Zhijia

Feng, Zhen; Li, Xiaoye; Tong, Wai Kei; He, Qingfeng; Zhu, Xiao; Xiang, Xiaoqiang; Tang, Zhijia.

Afiliación

Feng Z; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Li X; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Tong WK; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
He Q; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Zhu X; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Xiang X; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Tang Z; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.

Front Pharmacol ; 13: 894685, 2022.

Article en En | MEDLINE | ID: mdl-36506552

Palabras clave

FAERS; PCSK9 inhibitors; age-and gender-tailored treatment; alirocumab; drug safety; evolocumab; pharmacovigilance

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google